Spectrum and risk factors of invasive fungal infection
In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and...
Gespeichert in:
| Veröffentlicht in: | Enfermedades infecciosas y microbiología clínica 2007-08, Vol.25 (7), p.467 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 467 |
| container_title | Enfermedades infecciosas y microbiología clínica |
| container_volume | 25 |
| creator | Osorio, Juan José Castón Román, Antonio Rivero Torre-Cisneros, Julián |
| description | In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and other filamentous molds. Moreover, new risk factors for invasive fungal infection have been identified and the time of onset is different from that seen a decade ago. Recognition of these trends in patients receiving novel immunosuppressive regimens has important implications for the clinical management of fungal infection in this population. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_17692214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17692214</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-d472de790dfc2121fd033c04acf83df9ae05500726e57c0c6864020f3470b0fa3</originalsourceid><addsrcrecordid>eNo1jstKQzEURTNQ2lr9BckPXDg5J4_eoRRfUHBgB85KmuSUaO-DpLfg31tQR5sFi8W-EgtARQ2A-ZiLm1o_AdAQ0UzMlbMtotILYd_HFE5l6qTvoyy5fkn24TSUKgeWuT_7ms9J8tQf_PHCfLHz0N-Ka_bHmu7-dim2T4_b9UuzeXt-XT9smtFo3UTtMCbXQuSAChVHIAqgfeAVRW59AmMAHNpkXIBgV1YDApN2sAf2tBT3v9lx2ncp7saSO1--d___6QcVQT_0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Spectrum and risk factors of invasive fungal infection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Osorio, Juan José Castón ; Román, Antonio Rivero ; Torre-Cisneros, Julián</creator><creatorcontrib>Osorio, Juan José Castón ; Román, Antonio Rivero ; Torre-Cisneros, Julián</creatorcontrib><description>In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and other filamentous molds. Moreover, new risk factors for invasive fungal infection have been identified and the time of onset is different from that seen a decade ago. Recognition of these trends in patients receiving novel immunosuppressive regimens has important implications for the clinical management of fungal infection in this population.</description><identifier>ISSN: 0213-005X</identifier><identifier>PMID: 17692214</identifier><language>spa</language><publisher>Spain</publisher><subject>Adult ; Antifungal Agents - administration & dosage ; Antifungal Agents - therapeutic use ; Antineoplastic Agents - adverse effects ; Aspergillosis - drug therapy ; Aspergillosis - epidemiology ; Child ; Cross Infection - drug therapy ; Cross Infection - epidemiology ; Cross Infection - microbiology ; Female ; Fungemia - drug therapy ; Fungemia - epidemiology ; Fungemia - prevention & control ; Humans ; Immunocompromised Host ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - classification ; Infant ; Male ; Mycoses - drug therapy ; Mycoses - epidemiology ; Mycoses - prevention & control ; Neutropenia - chemically induced ; Neutropenia - complications ; Risk Factors ; Spain - epidemiology ; Zygomycosis - drug therapy ; Zygomycosis - epidemiology</subject><ispartof>Enfermedades infecciosas y microbiología clínica, 2007-08, Vol.25 (7), p.467</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17692214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osorio, Juan José Castón</creatorcontrib><creatorcontrib>Román, Antonio Rivero</creatorcontrib><creatorcontrib>Torre-Cisneros, Julián</creatorcontrib><title>Spectrum and risk factors of invasive fungal infection</title><title>Enfermedades infecciosas y microbiología clínica</title><addtitle>Enferm Infecc Microbiol Clin</addtitle><description>In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and other filamentous molds. Moreover, new risk factors for invasive fungal infection have been identified and the time of onset is different from that seen a decade ago. Recognition of these trends in patients receiving novel immunosuppressive regimens has important implications for the clinical management of fungal infection in this population.</description><subject>Adult</subject><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillosis - epidemiology</subject><subject>Child</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - microbiology</subject><subject>Female</subject><subject>Fungemia - drug therapy</subject><subject>Fungemia - epidemiology</subject><subject>Fungemia - prevention & control</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - classification</subject><subject>Infant</subject><subject>Male</subject><subject>Mycoses - drug therapy</subject><subject>Mycoses - epidemiology</subject><subject>Mycoses - prevention & control</subject><subject>Neutropenia - chemically induced</subject><subject>Neutropenia - complications</subject><subject>Risk Factors</subject><subject>Spain - epidemiology</subject><subject>Zygomycosis - drug therapy</subject><subject>Zygomycosis - epidemiology</subject><issn>0213-005X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jstKQzEURTNQ2lr9BckPXDg5J4_eoRRfUHBgB85KmuSUaO-DpLfg31tQR5sFi8W-EgtARQ2A-ZiLm1o_AdAQ0UzMlbMtotILYd_HFE5l6qTvoyy5fkn24TSUKgeWuT_7ms9J8tQf_PHCfLHz0N-Ka_bHmu7-dim2T4_b9UuzeXt-XT9smtFo3UTtMCbXQuSAChVHIAqgfeAVRW59AmMAHNpkXIBgV1YDApN2sAf2tBT3v9lx2ncp7saSO1--d___6QcVQT_0</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>Osorio, Juan José Castón</creator><creator>Román, Antonio Rivero</creator><creator>Torre-Cisneros, Julián</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200708</creationdate><title>Spectrum and risk factors of invasive fungal infection</title><author>Osorio, Juan José Castón ; Román, Antonio Rivero ; Torre-Cisneros, Julián</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-d472de790dfc2121fd033c04acf83df9ae05500726e57c0c6864020f3470b0fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillosis - epidemiology</topic><topic>Child</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - microbiology</topic><topic>Female</topic><topic>Fungemia - drug therapy</topic><topic>Fungemia - epidemiology</topic><topic>Fungemia - prevention & control</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - classification</topic><topic>Infant</topic><topic>Male</topic><topic>Mycoses - drug therapy</topic><topic>Mycoses - epidemiology</topic><topic>Mycoses - prevention & control</topic><topic>Neutropenia - chemically induced</topic><topic>Neutropenia - complications</topic><topic>Risk Factors</topic><topic>Spain - epidemiology</topic><topic>Zygomycosis - drug therapy</topic><topic>Zygomycosis - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osorio, Juan José Castón</creatorcontrib><creatorcontrib>Román, Antonio Rivero</creatorcontrib><creatorcontrib>Torre-Cisneros, Julián</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Enfermedades infecciosas y microbiología clínica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osorio, Juan José Castón</au><au>Román, Antonio Rivero</au><au>Torre-Cisneros, Julián</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spectrum and risk factors of invasive fungal infection</atitle><jtitle>Enfermedades infecciosas y microbiología clínica</jtitle><addtitle>Enferm Infecc Microbiol Clin</addtitle><date>2007-08</date><risdate>2007</risdate><volume>25</volume><issue>7</issue><spage>467</spage><pages>467-</pages><issn>0213-005X</issn><abstract>In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and other filamentous molds. Moreover, new risk factors for invasive fungal infection have been identified and the time of onset is different from that seen a decade ago. Recognition of these trends in patients receiving novel immunosuppressive regimens has important implications for the clinical management of fungal infection in this population.</abstract><cop>Spain</cop><pmid>17692214</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0213-005X |
| ispartof | Enfermedades infecciosas y microbiología clínica, 2007-08, Vol.25 (7), p.467 |
| issn | 0213-005X |
| language | spa |
| recordid | cdi_pubmed_primary_17692214 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antifungal Agents - administration & dosage Antifungal Agents - therapeutic use Antineoplastic Agents - adverse effects Aspergillosis - drug therapy Aspergillosis - epidemiology Child Cross Infection - drug therapy Cross Infection - epidemiology Cross Infection - microbiology Female Fungemia - drug therapy Fungemia - epidemiology Fungemia - prevention & control Humans Immunocompromised Host Immunosuppressive Agents - adverse effects Immunosuppressive Agents - classification Infant Male Mycoses - drug therapy Mycoses - epidemiology Mycoses - prevention & control Neutropenia - chemically induced Neutropenia - complications Risk Factors Spain - epidemiology Zygomycosis - drug therapy Zygomycosis - epidemiology |
| title | Spectrum and risk factors of invasive fungal infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spectrum%20and%20risk%20factors%20of%20invasive%20fungal%20infection&rft.jtitle=Enfermedades%20infecciosas%20y%20microbiolog%C3%ADa%20cl%C3%ADnica&rft.au=Osorio,%20Juan%20Jos%C3%A9%20Cast%C3%B3n&rft.date=2007-08&rft.volume=25&rft.issue=7&rft.spage=467&rft.pages=467-&rft.issn=0213-005X&rft_id=info:doi/&rft_dat=%3Cpubmed%3E17692214%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17692214&rfr_iscdi=true |